Purpose: Studies concerning mortality in epilepsy have been performed primarily in Northern-Central Europe and US. The aim of this study was to provide information about mortality in people with epilepsy in Southern European countries. Method: We studied a Spanish prevalence and incidence cohort of 2309 patients aged 14 years with epilepsy who were treated in an outpatient epilepsy clinic between 2000 and 2013. The deceased were identified through Civil Registries. Causes of death were determined using death certificates, forensic autopsies, hospital reports, family practitioners, and care-givers' records. Standardised mortality ratios (SMRs) were calculated. Results: In a total of 15,865 person-years of follow-up, 152 patients died, resulting in an SMR of 2.11 (95% CI 1.79-2.47), which was higher for those aged 14-24. There was also a high rate of death for symptomatic epilepsies, progressive causes (SMR = 6.12, CI 3.50-9.94), and remote causes (SMR = 2.62, CI 2.12-3.21). High SMRs were found for all kinds of epilepsy and for respiratory and tumoural causes. Patients who died of epilepsy itself were 12.5%. Sudden unexpected death in epilepsy incidence was 0.44:1000. Death from status epilepticus incidence was 20:100,000. SMRs for external causes were of no statistical significance. Conclusions: This is the first epidemiological study to examine rate of mortality in epilepsy in a Southern European country. The identified mortality pattern is similar to the one provided by researchers from developed countries. The similarities between our results concerning epilepsy-related deaths and those provided by population-based studies are the result of the scarcely selected character of our study cohort.
Introduction
Over the last 100 years, several epidemiological studies of mortality in epilepsy have been conducted worldwide. They have shown that people with epilepsy have a higher risk of premature death than the general population [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] .
Most of these studies have been conducted in Northern and Central European countries [1, 2, [4] [5] [6] [7] [8] [10] [11] [12] [13] [14] [15] [16] [17] , and there is only one study of scientific significance, performed in France [9] , that provides information about mortality in epileptic patients in Southern Europe. Neurologists in our area are forced to extrapolate information provided by studies from other countries.
Most of these studies point to an increase in risk of premature death between two and three in comparison to the reference population, although some provide smaller [1, 4, 7, 9] or higher [2, 6, 8] values. Results are primarily determined by the definition and classification of epilepsy, the study design, and the identification of the deceased and the causes of death [18] . Studies concerning the general population show an overall better prognosis. Those carried out in selected populations provide prognosis primarily determined by the way the population was selected and the severity of the disease. Studying prevalence, incidence, or mixed cohorts also influences the variation of the results [19] . The size of the sample and the follow-up time, clearly specified in person-years of follow-up, are also crucial.
We present our epidemiological study of mortality in epilepsy conducted in a large historical hospital-based Spanish cohort of prevalence and incidence cases. The special features of our Health System (explained in Methods) allow us to have an approach to epidemiological data although it is a hospital-based study. Our results about mortality in a centre that fulfils the criteria for a Medical Epilepsy Unit aim to provide some knowledge in an, until now, unstudied field in our geographic area.
Methods

Patients
We recruited all patients diagnosed with epilepsy and treated at the outpatient Epilepsy Unit at the Department of Neurology, Virgen de la Victoria University Hospital, in Málaga, Spain, between January 1, 2000 and June 30, 2013. This hospital provides health assistance to more than 50% of the Málaga city and province population (over 800,000 inhabitants). Health Care in Spain has been free for all citizens, including the indigent population. During the study period, it was the only public centre in the area for neurological patients to receive care, serving patients with epilepsy who were aged 14 years or above, referred by family practice physicians, neurologists, other specialists, emergency units, and by physicians who work in nursing homes and other institutions in the area. Accordingly, most of the patients with epilepsy from the west part of Málaga province and capital visit our Epilepsy Unit. The patients who we do not have contact with are those who prefer private neurological assistance, those in longterm remission who are followed up by their family physician, and those whose doctors have decided not to refer them to a neurologist. Therefore, a certain bias toward more severe cases may be expected.
For those patients who were already being treated in our Epilepsy Unit before the start of the study, we considered January 1, 2000 to be their entry date. For the rest of the patients, we considered their entry date as the first time they were examined in our clinic. The end date of the follow-up was either the patient's death or the end of the observation period. For those patients who were lost to follow-up, we consider the date of leaving the study to be last time they have a registered visit in our database.
Methods
We entered all demographic and clinical data of the study cohort in a database created for the study. All patients already diagnosed or suspected of having epilepsy are referred to the Epilepsy Unit and examined by a neurologist who specialises in the treatment of epilepsy. The patients undergo an electroencephalogram (EEG) and at least one imaging test (either a cranial computerized tomography [CT] scan or nuclear magnetic resonance imaging [NMRI] of the brain). If necessary, we repeat the NMRI at a higher level to get an accurate etiological diagnosis of remote symptomatic or cryptogenic epilepsy.
All patients' diagnosis of epilepsy, aetiology diagnosis, and seizure classification were revised to make sure they fulfilled the criteria for the International League Against Epilepsy (ILAE) [20] [21] [22] . We did not use the updated 2010 classification, because it would have made it difficult to compare our study to the previous studies. Having had two unprovoked seizures or just one seizure associated with a brain alteration that increased the risk of recurrence were the established criteria [22] . Patients with only acute symptomatic seizures were excluded. Epilepsies were classified as idiopathic, cryptogenic, or symptomatic. Those patients in the symptomatic category were divided into remote and progressive, according to the ILAE criteria [21] . Progressive neurologic conditions associated with epilepsy include neoplasms, autoimmune diseases, metabolic errors, neurodegenerative diseases, and chronic infections. The patients with remote symptomatic epilepsy were classified by cause: congenital, vascular, traumatic, infectious, toxic-metabolic, posttumoural-postsurgical, and mesial temporal sclerosis.
Deceased patients were identified using the Spanish Ministry of Justice INFOREG software. This system connects all national computerized Civil Registries. We introduced each patient's filiation data to check if there was a corresponding death certificate. However, this system does not provide information about deaths that occurred abroad. To find the cause of death, we gathered copies or transcripts of original death certificates that reported the primary and immediate cause of death for those cases that were possible to determine by that method. We obtained detailed information of all the judicial autopsies performed in Legal Medicine Institutes. We asked for permission from the judge responsible in each Civil Registry. Hospital reports on mortality were consulted for those patients who died in the hospital. If a patient died at home, we gathered information from the family practice physicians and emergency units. Causes of death were divided into non-epilepsy-related (respiratory, tumoural, cerebrovascular, cardiac, and miscellaneous) and epilepsy-related (sudden unexpected death in epilepsy [SUDEP], status epilepticus [SE], suicide, accident, and treatment-related). SUDEP is defined according to the most commonly accepted criteria [23] . All the SUDEP cases had an autopsy report and they were classified as definite SUDEP.
Statistical Analysis
We calculated mortality rate as the number of deaths in our cohort in the observation time divided by the person-years at risk, and case fatality as the number of deaths divided by the number of subjects with the disease in our cohort. We calculated the standardized mortality ratios (SMRs) for all the patients by gender, age group, epilepsy type and aetiology, and causes of death. To calculate expected deaths, we used data from the Statistical National Institute for the population of Málaga during the study period [24] . SMRs have been standardised for gender, age, and period of death-year. We calculated proportional mortality for the different causes of death. For all confidence intervals (CI), we considered a confidence level of 95%. We calculated the incidence of SUDEP as the number of SUDEP cases in our cohort in the observation time divided by the person-years at risk.
Results
The study cohort included 2,309 patients (1,264 men, 1,045 women). Average entry age for the study was 38.5 years, with a standard deviation (sd) of 17.5. Follow-up time was 13.5 years, with an average follow-up time of 6.9 years (sd = 3.8). There were 15,865 person-years of follow-up. Thirty-five patients were lost to followup (1.94%). One hundred fifty-two patients (101 men, 51 women) died during the course of the study. Demographic data and clinical characteristics of the study cohort and the deceased patients are detailed in Table 1 .
Mortality rate was 9.69 per 1,000 patient-years. Case fatality was 6.58%. Overall SMR was 2.11 (95% CI 1.79-2.47). SMR for men was 2.13 (95% CI 1.73-2.59) and 1.91 (95% CI 1.45-2.51) for women. Highest SMR was found for those between 14 and 44 years of age for both sexes (Table 2) .
We found high SMR for generalised epilepsies (SMR = 2.49, 95% CI 1.76-3.41), for focal, with or without secondary generalisation (SMR = 1.93, 95% CI 1.55-2.38), and for undetermined (SMR = 2.29, 95% CI 1.51-3.33).
We did not find a statistically significant increase in SMR for patients with cryptogenic (SMR = 1.20, 95% CI 0.82-1.70) and idiopathic (SMR = 1.34, 95% CI 0.64-2.47) epilepsies, not even when we considered both groups together (SMR = 1.23, 95% CI 0.88-1.67). There was a higher mortality rate for patients with symptomatic epilepsy: SMR = 6.12 (95% CI3.50-9.94) for the progressive symptomatic group and SMR = 2.62 (95% CI 2.12-3.21) for the remote symptomatic group. Within this last group, the highest SMR was for patients with congenital epilepsy (Table 3) .
Cause of death was determined in 146 cases. We used death certificates of 122 patients (80.3%), autopsies of 17 patients (11.2%), hospital death reports of 73 patients (48.0%), family practice physicians' reports of 13 patients (8.6%), and information provided by witnesses of the patient's death in four cases (2.6%). For all cases, additional information from primary care reports and specialised units was gathered. For causes of death, proportional mortality is shown in Table 4 , and SMRs for the different categories are provided in Table 5 . One hundred twenty-seven patients died from non-epilepsy-related causes. The highest SMR was found for overall respiratory diseases. There were also high SMRs for tumoural causes of death, both when central nervous system (CNS) tumours were included in and excluded from the analysis. We did not find high SMRs for cardiac causes of death. SMR for cerebrovascular causes was high, but did not reach statistical significance. Nineteen patients died of epilepsy. We did not find statistical significance in SMRs for external death causes (suicide and accidents). Incidence of SUDEP was 0.4:1000 patient-years of follow-up. There were seven cases related to SUDEP. Death for SE incidence was 20:100,000 patient-years of follow-up. 
Discussion
To our knowledge, this is the first epidemiological study of mortality in epilepsy to be conducted in a Southern European country, and more specifically, in Spain.
In our Health Assistance system, every patient with epilepsy, whatever the severity of the disease, can receive special care. Therefore, not only the most severely affected patients, but also patients with more benign diseases are attended in our clinic. There is also the common circumstance by which patients who are likely to have epilepsy are referred to a neurologist at some point. These circumstances lead most of the people with epilepsy, although not all, to be examined in our Epilepsy Unit. Thus, the group of patients with epilepsy treated in our clinic is in many ways similar to the group of patients with epilepsy in the general population, in contrast to those treated in tertiary care centres. As it was analysed and published elsewhere [25] , our population may be representative of people with epilepsy in Málaga, and similar to other patients with epilepsy in Europe, but not all. Taking this into account, we can compare our study to those related to mortality in patients with epilepsy. The analysis of our mixed cohort, prevalence and incidence, of patients diagnosed with epilepsy is representative of the Medical Epilepsy Unit as the first step in assisting epileptic patients. We consider the study conducted in Tirol, Austria [17] , to be the one designed most similarly to ours. A great advantage of studies such as these, conducted using large hospital-based cohorts, is that they are more precise in the diagnosis of the disease [18] , and the classification of epilepsy by its aetiology and seizure typing [17] . A uniform and comprehensive approach to epilepsy diagnosis and classification for all the subjects in the cohort permits more reliable investigation of the relationship between epilepsy mortality aetiology and mortality. These studies actually measure mortality in epilepsy, whereas general population-based studies can increase biased diagnosis. As the start date of our observation was the year 2000, most of the patients were examined using a NMRI of the brain to determine disease aetiology, which allowed a precise etiologic diagnosis.
The number of patients registered in our unit during the study period is significant, with a total of 2,309 patients and a follow-up period of 13.5 years. The number of person-years of follow-up in our study is 15,865. With some exceptions, such as the recently published large Finish study [16] , studies for the general population show a smaller number of patients in study than those for selected cohorts.
We have found an increase in mortality for our patients with epilepsy, approximately double in comparison to the reference population. This is similar to those found in other studies conducted in developed countries for the general population [3, 5, 10, 11, 13] and selected cohorts [12, 17] . Mortality was higher among men, or similar between men and women (as in ours), in most of the published studies. There are two studies [5, 14] in which the mortality was higher in women with epilepsy than in men, but the authors recognize that this fact is difficult to interpret. The reason for this remains unclear. In relation to age, the highest increase in mortality was found among the youngest patients, with the highest SMR for patients aged 14-24 years, decreasing as age goes up. Most studies show similar values. This shows how low expected mortality is for the youngest age groups in reference populations and indicates that increased premature mortality is mainly related to the cause of epilepsy and, more specifically, to neurological deficits from birth causing remote symptomatic congenital epilepsy.
In our study, there is an increased premature mortality for patients with symptomatic epilepsies, similarly to all worldwide studies. This finding demonstrates that symptomatic aetiology of epilepsy is an ultimate factor in determining mortality in patients with epilepsy. However, there are some variations concerning how much it increases, resulting primarily from the underlying aetiologies included or not in the analysis. Our study is one of the few to distinguish between progressive and remote symptomatic aetiology. The highest SMR was found for progressive aetiology. We studied SMR for different subgroups of remote symptomatic epilepsy and found that the highest mortality is that associated with congenital aetiology, followed by toxic-metabolic, post-traumatic, and cerebrovascular. The present study did not find an increase in mortality for epilepsies with asymptomatic aetiologies, similarly to Callaghan's study [26] . Most of the published studies do not distinguish between idiopathic and cryptogenic aetiology, especially those based on the general population. Some studies have pointed to a high SMR for cryptogenic aetiology [12, 14, 17] , except for the one conducted in France by Loiseau [9] . A recent meta-analysis [27] also calculates a high relative risk for cryptogenic aetiology, but not for idiopathic.
In our study, we found an increase of mortality for all types of epilepsy (generalized, focal, and undetermined). Studies conducted in more selected populations also indicate this [15, 17] , although population studies show more irregular results. It could be argued that these studies establish the type of epilepsy less accurately, as the study designs do not allow in many cases the direct classification by an epilepsy expert.
We studied causes of death. Incorrect death certificates usually are an important source of bias [18, 28] . It is therefore crucial to consult other sources of information such as autopsies, and hospital and family practice physicians' reports on mortality, as we have done in our study. We have reported that most patients (83.6%) died due to causes non-strictly related to epilepsy. In consistent accordance with most studies, mortality is increased by respiratory [2, 3, 5, 6, 8, [11] [12] [13] 16, 29] and tumoural [2, 3, 5, 6, 8, [11] [12] [13] 15, 17, 29] diseases, even after excluding CNS tumours from the analysis. In contrast, results vary to a great extent for cardiac causes, with some studies showing high SMRs [6, 15, 29] and others not finding them [12, 17] . Proportional mortality strictly attributed to epilepsy was 12.5%. We found low incidence of SUDEP and SE. The autopsies have allowed us to identify SUDEP as it is defined according to the most commonly accepted criteria [23] , but it is likely that deaths secondary to SUDEP were underreported, as they likely have been in previous studies, given the low number of autopsies performed. SMRs were of no statistical significance for external causes. Recent studies of the general population, as the one performed in Sweden by Fazel et al. [30] , have shown an increase in premature mortality for external causes among patients with epilepsy. The fact that our results in relation to deaths caused directly by epilepsy are similar to those found in population-based studies [3, 5, 9, 10] could be explained if we consider the lack of selectivity for our epileptic hospital-based population in relation to the severity of the disease and the importance of conducting studies with a larger number of personyears of follow-up.
Limitations and strengths
A weakness of our study resides in the fact that results cannot be extrapolated to the total of people with epilepsy in Málaga, as it was not carried out at the general population level, although it is valid to get an estimation of the mortality of patients with epilepsy treated in a medical epilepsy unit. We believe there to be a bias in the estimation of the initial mortality, as we studied a prevalent and incident population. Age at the onset of epilepsy, time of evolution, and clinical severity could not be studied as risk factors. The low number of autopsies is a potential source of error. Among the main strengths of our study are the accurate diagnosis and classification of epilepsy, and the care taken in retrieving the death certificates and to determinate the causes of death. The minimal number of patients lost to follow-up also supports our results.
Conclusions
This is the first epidemiological study of mortality in epilepsy conducted in Spain and in Southern Europe. The mortality pattern identified in our hospital Epilepsy Clinic shows that patients with epilepsy have a higher SMR. This increase in mortality is higher in younger age groups, for all types of epilepsy and for symptomatic epilepsies (progressive and remote). Most deaths are due to natural and non-strictly related to epilepsy causes. The mortality pattern found in our study is similar to the ones provided by researchers from developed countries. Due to the lack of case selection by severity of the disease in our area, the mortality profile strictly attributable to epilepsy is similar to those provided by studies of mortality in epilepsy for the general population.
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